Step Pharma is financed to move its pipeline-in-a-product strategy forward on a broad front, after raising a €38 million (US$44.2 million) series C. That will see three ongoing trials testing the company’s potentially first-in-class, orally available cytidine triphosphate synthase 1 inhibitor, dencatistat, through to phase II in T-cell and B-cell lymphoma, in an ovarian, endometrial and lung cancer study, and in essential thrombocythemia.
Comind Technologies Ltd. secured $60 million in funding for its optical neuromonitoring device which non-invasively measures key physiological parameters of the brain to provide critical information on its health. The technology could significantly improve the way the brain is monitored by addressing key challenges of current methods such as inaccuracy, invasiveness and limited availability when needed.
The U.K. Competition and Markets Authority (CMA) has issued draft guidelines for remedies for mergers and acquisitions, which the agency insists incorporates some regulatory flexibility. However, CMA said its approach is premised on the notion that any regulated transaction should have zero effect on competition in the affected industry, a premise that would seem to quash any transaction that leads to fewer companies in that industry.
The U.K. Medicines and Healthcare Products Regulatory Agency reported the winners of the second phase of the AI Airlock challenge, which includes the Tortus AI, a medical scribe system developed by physicians in the U.K. National Health Service.
There was a curate’s egg for Sanofi SA from this month’s meeting of the EMA’s Committee for Medicinal Products for Human Use, with a recommendation to approve one of the French pharma’s drugs – and the rejection of another.
A year and half from its inception, Adcytherix SAS has raised a €105 million (US$122 million) series A, enabling it to take the lead antibody-drug conjugate (ADC) program into clinical development next year.
Antibody-drug conjugate (ADC) specialist Aimedbio Inc. announced Oct. 16 the signing of a potential $991 million deal with Boehringer Ingelheim GmbH to license out its novel preclinical ADC asset targeting solid tumors, including KRAS mutations, which is set to enter phase I study next year.
A year and half from its inception, Adcytherix SAS has raised a €105 million (US$122 million) series A, enabling it to take the lead antibody-drug conjugate (ADC) program into clinical development next year.
Aicuris Anti-Infective Cures AG is preparing to file for U.S. FDA approval after reporting positive phase III results for lead antiviral pritelivir in the healing of refractory herpes simplex virus lesions in immunocompromised patients.
Antibody-drug conjugate specialist Tubulis GmbH has raised a hefty €308 million (US$356 million) series C to expand clinical development of TUB-040, positioning its lead program for use in additional indications and as an earlier line of therapy.
RSS
